


**Figure S1. Laboratory tests before and after <sup>68</sup>Ga-IRDye800CW-BBN administration (*n* = 10).**

A. Red blood cell count (RBC; reference:  $3.8 - 5.1 \times 10^{12}/L$ ). B. White blood cell count (WBC; reference:  $3.5 - 9.5 \times 10^9/L$ ). C. Platelet count (PLT; reference:  $125 - 350 \times 10^9/L$ ). D. Glutamic-pyruvic transaminase (ALT; reference:  $0 - 41$  U/L). E. Glutamic-oxaloacetic transaminase (AST; reference:  $0 - 42$  U/L). F. Creatinine (Cre; reference:  $31.7 - 93.3$  μmol/L). \*\*,  $P < .05$ ; ns,  $P > .05$  not significant.



**Figure S2. Laboratory tests before and after IRDye800CW-BBN administration (n = 52).**

A. Red blood cell count (RBC; reference:  $3.8 - 5.1 \times 10^{12}/L$ ). B. White blood cell count (WBC; reference:  $3.5 - 9.5 \times 10^9/L$ ). C. Platelet count (PLT; reference:  $125 - 350 \times 10^9/L$ ). D. Glutamic-pyruvic transaminase (ALT; reference:  $0 - 41$  U/L). E. Glutamic-oxaloacetic transaminase (AST; reference:  $0 - 42$  U/L). F. Creatinine (Cre; reference:  $31.7 - 93.3 \mu\text{mol}/L$ ). \*\*,  $P < .05$ ; \*\*\*,  $P < .01$ , \*\*\*\*,  $P < .001$ ; ns,  $P > .05$  not significant.